Evidence map›Paper›PMID 41642357›Full record

ArticleBiotechnology letters2026

Evaluation of cultivation performance of S. cerevisiae strains expressing GLP-1-GIP peptide precursors.

Ioannis Voulgaris, Anders Nygaard Nielsen, Tine Petersen, Jakob Brandt, Sanne Jensen

Abstract read
PubMed Publisher
In one paragraph

Article in Biotechnology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ioannis VoulgarisTherapeutic Discovery, Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Måløv, Denmark. IVO@novonordisk.com.ORCID http://orcid.org/0000-0001-8367-3224
Anders Nygaard NielsenTherapeutic Discovery, Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Måløv, Denmark.
Tine PetersenTherapeutic Discovery, Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Måløv, Denmark.
Jakob BrandtTherapeutic Discovery, Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Måløv, Denmark.
Sanne JensenTherapeutic Discovery, Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Måløv, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Strains of S. cerevisiae expressing GLP-1-GIP peptide precursors with an N-terminal extension demonstrate up to 29% higher molar productivity during continuous cultivation compared to non-extended counterparts. Additionally, inactivation of the S. cerevisiae AMN1 gene, through deletion, effectively reduces broth viscosity by more than 45%, thereby enhancing oxygen transfer without adversely affecting cell metabolism or product titer. These results highlight the advantages of molecular modifications and genetic alterations for improving the production efficiency of GLP-1 receptor agonists, addressing critical challenges related to recombinant expression, viscosity and oxygen transfer in bioprocessing.

Indexed as

Glucagon-Like Peptide 1Protein PrecursorsSaccharomyces cerevisiaeFermentationRecombinant ProteinsSaccharomyces cerevisiae ProteinsViscosityGlucagon-Like Peptide 1Protein PrecursorsRecombinant ProteinsSaccharomyces cerevisiae ProteinsAMN1FermentationGLP-1-GIP peptideN-terminal extensionS. cerevisiaeViscosity

Identifiers

PMID41642357

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.